These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710 [TBL] [Abstract][Full Text] [Related]
3. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886 [TBL] [Abstract][Full Text] [Related]
4. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
5. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Muliaditan T; Halim L; Whilding LM; Draper B; Achkova DY; Kausar F; Glover M; Bechman N; Arulappu A; Sanchez J; Flaherty KR; Obajdin J; Grigoriadis K; Antoine P; Larcombe-Young D; Hull CM; Buus R; Gordon P; Grigoriadis A; Davies DM; Schurich A; Maher J Cell Rep Med; 2021 Dec; 2(12):100457. PubMed ID: 35028604 [TBL] [Abstract][Full Text] [Related]
6. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X Front Immunol; 2020; 11():539654. PubMed ID: 33281809 [TBL] [Abstract][Full Text] [Related]
7. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy. Gallego-Valle J; Pérez-Fernández VA; Rosales-Magallares J; Gil-Manso S; Castellá M; Gonzalez-Navarro EA; Correa-Rocha R; Juan M; Pion M Front Immunol; 2024; 15():1448752. PubMed ID: 39364400 [TBL] [Abstract][Full Text] [Related]
8. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369 [TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities. Ho M; Zanwar S; Paludo J Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132 [TBL] [Abstract][Full Text] [Related]
10. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221 [TBL] [Abstract][Full Text] [Related]
11. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204 [TBL] [Abstract][Full Text] [Related]
12. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia. Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104 [TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370 [TBL] [Abstract][Full Text] [Related]
14. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575 [TBL] [Abstract][Full Text] [Related]
15. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J Front Immunol; 2022; 13():836549. PubMed ID: 35222427 [TBL] [Abstract][Full Text] [Related]
16. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641 [TBL] [Abstract][Full Text] [Related]
17. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371 [TBL] [Abstract][Full Text] [Related]
19. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319 [TBL] [Abstract][Full Text] [Related]
20. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype. Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]